Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
5.83
-0.16 (-2.67%)
At close: Oct 29, 2024, 4:00 PM
5.80
-0.03 (-0.51%)
After-hours: Oct 29, 2024, 4:11 PM EDT
Sagimet Biosciences Revenue
Sagimet Biosciences had revenue of $2.00M in the twelve months ending June 30, 2024. In the year 2023, Sagimet Biosciences had annual revenue of $2.00M.
Revenue (ttm)
$2.00M
Revenue Growth
n/a
P/S Ratio
74.64
Revenue / Employee
$200,000
Employees
10
Market Cap
186.06M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.00M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
TruBridge | 336.56M |
LifeMD | 178.28M |
Fulcrum Therapeutics | 81.63M |
Zentalis Pharmaceuticals | 40.56M |
MediWound | 20.14M |
Cellectis | 19.64M |
Vaxart | 13.93M |
SGMT News
- 11 days ago - Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat - Seeking Alpha
- 18 days ago - Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology - GlobeNewsWire
- 4 weeks ago - Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH - GlobeNewsWire
- 4 weeks ago - Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit - GlobeNewsWire
- 3 months ago - Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors - GlobeNewsWire
- 3 months ago - Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide - Seeking Alpha
- 5 months ago - Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat - GlobeNewsWire